Counting pyrazinamide in regimens for multidrug-resistant tuberculosis

Annals of the American Thoracic Society

Volumn 12, Issue 5, 2015, Pages 674-679

  Franke, Molly F ^a,b   Becerra, Mercedes C ^a,b,c   Tierney, Dylan B ^c   Rich, Michael L ^b,c   Bonilla, Cesar ^d   Bayona, Jaime ^e   McLaughlin, Megan M ^a   Mitnick, Carole D ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SOCIOS EN SALUD   (Peru)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MINISTERIO DE SALUD   (Peru)

^e WORLD BANK GROUP   (United States)

Author keywords

Drug resistance; Mortality; Tuberculosis drug therapy

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; ADULT; AGED; DRUG EFFECTS; FEMALE; FOLLOW UP; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84929616401     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201411-538OC     Document Type: Article

References (32)

1. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, et al.; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
2. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-161.
3. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009;4:e6914.
4. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-481.
5. st ed. Geneva, Switzerland: WHO; 2006.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, Switzerland: WHO; 2011.
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
8. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HSF, et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS ONE 2013;8:e58664.
9. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, Shin S, Murray M, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013;56: 770-776.
10. Tierney DB, Franke MF, Becerra MC, Alcantara Viru FA, Bonilla CA, Epifanio Sanchez E, Guerra D, Munoz M, Llaro K, Palacios E, et al. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS One 2014;9:e108035.
11. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis 2014;59:9-15.
12. World Health Organization. Framework for implementing new tuberculosis diagnostics. Geneva, Switzerland: WHO; 2010.
13. Dormandy J, Somoskovi A, Kreiswirth BN, Driscoll JR, Ashkin D, Salfinger M. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 2007;131:497-501.
14. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21.
15. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011;55:4499-4505.
16. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008;359:563-574.
17. Becerra MC, Appleton SC, Franke MF, Chalco K, Bayona J, Murray MB, Mitnick CD. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis 2010;51:709-711.
18. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MCS, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-128.
19. Partners In Health. The PIH guide to the medical management of multidrug-resistant tuberculosis. Boston, MA: Partners in Health; 2003.
20. Partners in Health, Harvard Medical School B& MGF. A DOTS-Plus handbook: guide to the community-based treatment of MDR-TB. Boston, MA: Harvard Medical School; 2002.
21. Fraser HSF, Jazayeri D, Mitnick CD, Mukherjee JS, Bayona J. Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp 2002;270-274.
22. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
23. Therneau TM, Grambsch PM. Modeling survival data. New York: Springer; 2000.
24. Shafer J. Analysis of incomplete multivariate data. New York: Chapman and Hall; 1997.
25. Chang K-C, Leung C-C, Yew W-W, Leung EC-C, Leung W-M, Tam C-M, Zhang Y. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012;56:5465-5475.
26. Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, et al.; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014;59:1364-1374.
27. Sokolova GB, Semenova OV, Bogadel'nikova IV, Kunichan AD. Effect of levofloxacine on cell elements of the lung tissue and on the growth of drug resistant Mycobacteria tuberculosis. (In Russian.) Antibiot Khimioter 2002;47:12-17.
28. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51:1011-1015.
29. Tasneen R, Li S-Y, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:5485-5492.
30. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS ONE 2011;6:e17556.
31. Hall RG, Leff RD, Gumbo T; Insights from the Society of Infectious Diseases Pharmacists. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Pharmacotherapy 2009;29:1468-1481.
32. Gumbo T, Dona CS, Meek C, Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009;53:3197-3204.